Cargando…

Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma

We describe molecular convergence between BMI1 and CHD7 in the initiation of medulloblastoma. Identified in a functional genomic screen in mouse models, a BMI1(High);CHD7(Low) expression signature within medulloblastoma characterizes patients with poor overall survival. We show that BMI1-mediated re...

Descripción completa

Detalles Bibliográficos
Autores principales: Badodi, Sara, Dubuc, Adrian, Zhang, Xinyu, Rosser, Gabriel, Da Cunha Jaeger, Mariane, Kameda-Smith, Michelle M., Morrissy, Anca Sorana, Guilhamon, Paul, Suetterlin, Philipp, Li, Xiao-Nan, Guglielmi, Loredana, Merve, Ashirwad, Farooq, Hamza, Lupien, Mathieu, Singh, Sheila K., Basson, M. Albert, Taylor, Michael D., Marino, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732319/
https://www.ncbi.nlm.nih.gov/pubmed/29212025
http://dx.doi.org/10.1016/j.celrep.2017.11.021
Descripción
Sumario:We describe molecular convergence between BMI1 and CHD7 in the initiation of medulloblastoma. Identified in a functional genomic screen in mouse models, a BMI1(High);CHD7(Low) expression signature within medulloblastoma characterizes patients with poor overall survival. We show that BMI1-mediated repression of the ERK1/2 pathway leads to increased proliferation and tumor burden in primary human MB cells and in a xenograft model, respectively. We provide evidence that repression of the ERK inhibitor DUSP4 by BMI1 is dependent on a more accessible chromatin configuration in G4 MB cells with low CHD7 expression. These findings extend current knowledge of the role of BMI1 and CHD7 in medulloblastoma pathogenesis, and they raise the possibility that pharmacological targeting of BMI1 or ERK may be particularly indicated in a subgroup of MB with low expression levels of CHD7.